MindMed Announces $25 Million Bought Deal Public Offering
October 9, 2020
Ryan Allway October 9th, 2020 Psychedelics, Top News NEW YORK, Oct. 9, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the... Read more
MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines
October 5, 2020
About MindMed MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine... Read more
Ryan Allway October 2nd, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has joined the Drug Science Medical... Read more
Dr. Dan Engle Joins Mind Cure’s Advisory Board
October 2, 2020
Ryan Allway October 2nd, 2020 Psychedelics Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce the addition of Dr. Dan Engle to the company’s scientific advisory board. Dr. Dan Engle is a world-renowned physician in both psychiatry and neurology and sits at the forefront of psychedelic... Read more
Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences
October 2, 2020
Ryan Allway October 2nd, 2020 Psychedelics AWAKN Life Sciences Inc. (“AWAKN”) is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB). Celia Morgan is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She is one Europe’s leading Ketamine... Read more
Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications
October 2, 2020
Ryan Allway October 2nd, 2020 Psychedelics Sansero Life Sciences, a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism... Read more
Why Psychedelic Delivery Mechanisms Matter
October 2, 2020
Ryan Allway October 2nd, 2020 App, Exclusive, News, Psychedelics, Top News The psychedelics industry is poised to become a nearly $7 billion market by 2027, according to Data Bridge Market Research, driven by the potential to revolutionize the treatment of mental health disorders. While investors have many options in... Read more
Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today
September 30, 2020
Ryan Allway September 30th, 2020 App, News, Top News DENVER, Colorado, USA – September 30th, 2020 – Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has... Read more
September 28, 2020 (Source) — Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce... Read more
Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
September 29, 2020
Ryan Allway September 29th, 2020 Psychedelics Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has entered into a definitive agreement with Psygen Labs Inc. (“Psygen”) for the supply of psilocybin for... Read more
